Table 1.
Patient characteristics of our study cohorts
| Patient characteristics | TCGA | NHS-HPFS | PLCO | |
|---|---|---|---|---|
| Number of patients | N = 628 | N = 927 | N = 333 | |
| Age (Standard Deviation) | 66.3 ± 12.8 | 62.4 ± 9.6 | 65.0 ± 4.7 | |
| Sex | Male | 334 (53.2%) | 413 (44.6%) | 213 (64.0%) |
| Female | 294 (46.8%) | 512 (55.3%) | 120 (36.0%) | |
| Race | Not Available | 255 (40.61%) | 390 (42.07%) | 175 (52.6%) |
| Black or African American | 65 (10.35%) | 8 (0.86%) | 8 (2.4%) | |
| White | 295 (46.97%) | 526 (56.74%) | 120 (36.0%) | |
| Asian | 12 (1.91%) | 3 (0.32%) | 26 (7.8%) | |
| Native American or Alaska Native | 1 (0.16%) | 0 (0%) | 0 (0.0%) | |
| Pacific Islander | 0 (0.0%) | 0 (0%) | 4 (1.2%) | |
| Tumor Location | Proximal Colon | 258 (42.5%) | 469 (50.4%) | 127 (38.1%) |
| Distal Colon | 185 (30.5%) | 280 (30.1%) | 88 (26.4%) | |
| Rectum | 164 (27.0%) | 181 (19.5%) | 118 (35.4%) | |
| Disease Stage | Stage I | 108 (17.2%) | 198 (21.4%) | 49 (14.7%) |
| Stage II | 229 (36.5%) | 281 (30.3%) | 64 (19.2%) | |
| Stage III | 181 (28.8%) | 248 (26.8%) | 50 (15.0%) | |
| Stage IV | 90 (14.3%) | 134 (14.5%) | 16 (4.8%) | |
| Unknown | 20 (3.2%) | 66 (7.1%) | 154 (46.2%) | |
| MSI | High | 65 (14.3%) | 150 (16.7%) | - |
| Low/negative | 389 (85.7%) | 750 (83.3%) | - | |
| BRAF mutation* | BRAF mutation in any loci | 62 (10.4%) | 136 (15.0%) | - |
| BRAF c.1799T > A (p.V600E) mutation | 48 (8.32%) | - | - | |
| Wild-Type | 529 (89.5%) | 770 (85.0%) | - | |
| CIMP | High | 58 (12.8%) | 155 (18.1%) | - |
| Low/negative | 396 (87.2%) | 703 (81.9%) | - | |
*Gene names are italicized.